{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:47:39Z","timestamp":1789660059959,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.neuropharm.2008.07.002","type":"journal-article","created":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T06:02:45Z","timestamp":1215756165000},"page":"133-138","source":"Crossref","is-referenced-by-count":85,"special_numbering":"S1","title":["Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: Neurotoxic and therapeutic implications"],"prefix":"10.1016","volume":"56","author":[{"given":"Annette E.","family":"Fleckenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent J.","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen R.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2008.07.002_bib1","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1046\/j.1471-4159.2000.0742221.x","article-title":"Methamphetamine rapidly decreases vesicular dopamine uptake","volume":"74","author":"Brown","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0022-3565(24)38814-7","article-title":"Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants","volume":"296","author":"Brown","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0022-3565(24)29485-4","article-title":"Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors","volume":"298","author":"Brown","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.302.2.497","article-title":"A single methamphetamine administration rapidly decreases vesicular dopamine uptake","volume":"302","author":"Brown","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib5","unstructured":"Chu, P.W., Seferian, K.S., Birdsall, E., Truong, J.G., Riordan, J.A., Metcalf, C.S., Hanson, G.R., Fleckenstein, A.E., in press. Differential regional effects of methamphetamine on dopamine transport. Eur. J. Pharmacol. (in press; PMID: 18599036)."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib6","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1523\/JNEUROSCI.14-04-02260.1994","article-title":"Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress","volume":"14","author":"Cubells","year":"1994","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(92)90201-J","article-title":"Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine","volume":"598","author":"Eisch","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1124\/jpet.104.072264","article-title":"Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum","volume":"312","author":"Eyerman","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1471-4159.2007.04837.x","article-title":"A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine","volume":"103","author":"Eyerman","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(24)37016-8","article-title":"Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration","volume":"283","author":"Fleckenstein","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.410400609","article-title":"Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging","volume":"40","author":"Frey","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib12","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1523\/JNEUROSCI.19-07-02424.1999","article-title":"Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice","volume":"19","author":"Fumagalli","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00500283","article-title":"Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity","volume":"310","author":"Gibb","year":"1979","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1046\/j.1471-4159.1995.64041819.x","article-title":"Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine","volume":"64","author":"Giovanni","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0306-4522(03)00476-7","article-title":"Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity","volume":"122","author":"Guilarte","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib16","unstructured":"Guillot, T.S., Richardson, J.R., Wang, M.Z., Li, Y.J., Taylor, T.N., Ciliax, B.J., Zachrisson, O., Mercer, A., Miller, G.W., in press. PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides (in press; PMID: 18533255)."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/jpet.300.3.1093","article-title":"Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity","volume":"300","author":"Hansen","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib18","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1046\/j.1471-4159.2000.0742217.x","article-title":"Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations","volume":"74","author":"Hogan","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib19","first-page":"257","article-title":"Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain","volume":"214","author":"Hotchkiss","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib20","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/0024-3205(79)90414-4","article-title":"The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase, and glutamate decarboxylase activities","volume":"25","author":"Hotchkiss","year":"1979","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00213-006-0330-6","article-title":"Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers","volume":"185","author":"Johanson","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0773.1999.tb00080.x","article-title":"Hydroxyl radical formation following methamphetamine administration to rats","volume":"85","author":"Kita","year":"1999","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0014-2999(76)90090-X","article-title":"Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activities and on striatal dopamine levels","volume":"36","author":"Kogan","year":"1976","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib24","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1523\/JNEUROSCI.22-20-08951.2002","article-title":"Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis","volume":"22","author":"Larsen","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib25","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1523\/JNEUROSCI.19-04-01484.1999","article-title":"Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine","volume":"19","author":"LaVoie","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.neuron.2005.09.033","article-title":"Sorting of vesicular monoamine transporter 2 to the regulated secretory pathway confers the somatodendritic exocytosis of monoamines","volume":"48","author":"Li","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1006\/exnr.1998.7008","article-title":"Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease","volume":"156","author":"Miller","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0028-3908(80)90010-6","article-title":"Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei","volume":"10","author":"Morgan","year":"1980","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib29","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1523\/JNEUROSCI.18-15-05575.1998","article-title":"D2-like dopamine autoreceptor activation reduces quantal size in PC12 cells","volume":"18","author":"Pothos","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuropharm.2005.05.004","article-title":"Bupropion increases striatal vesicular monoamine transport","volume":"49","author":"Rau","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/jpet.105.099200","article-title":"Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake","volume":"318","author":"Rau","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-2999(02)01985-4","article-title":"Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine","volume":"449","author":"Riddle","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2007.05.044","article-title":"Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2","volume":"571","author":"Riddle","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrn1583","article-title":"Synaptic vesicle pools","volume":"6","author":"Rizzoli","year":"2005","journal-title":"Nat. Rev."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib35","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1523\/JNEUROSCI.22-19-08705.2002","article-title":"Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors","volume":"22","author":"Sandoval","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.102.045005","article-title":"Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits","volume":"304","author":"Sandoval","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib37","first-page":"539","article-title":"Role of dopamine in the neurotoxic effects of methamphetamine","volume":"233","author":"Schmidt","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0376-8716(76)90030-2","article-title":"Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys","volume":"1","author":"Seiden","year":"1976","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib39","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1152\/physrev.1989.69.3.864","article-title":"Modulation of neurotransmitter release by presynaptic autoreceptors","volume":"69","author":"Starke","year":"1989","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0896-6273(00)00109-4","article-title":"The synaptic vesicle cycle revisited","volume":"28","author":"Sudhof","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","article-title":"Mechanisms of neurotransmitter release by amphetamines: a review","volume":"75","author":"Sulzer","year":"2005","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1460-9568.2007.05688.x","article-title":"Augmentation of methamphetamine-induced toxicity in the rat striatum by unpredictable stress: contribution of enhanced hyperthermia","volume":"26","author":"Tata","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib43","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0022-3565(24)36537-1","article-title":"Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake","volume":"280","author":"Teng","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"#cr-split#-10.1016\/j.neuropharm.2008.07.002_bib44.1","unstructured":"Thomas, D.M., Francescutti-Verbeem, D.M., Kuhn, D.M., in press. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem. (in press;"},{"key":"#cr-split#-10.1016\/j.neuropharm.2008.07.002_bib44.2","unstructured":"Epub ahead of print)."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0014-2999(03)02080-6","article-title":"Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration","volume":"474","author":"Truong","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2004.03.060","article-title":"Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration","volume":"492","author":"Truong","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2004.09.049","article-title":"Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein","volume":"504","author":"Truong","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib48","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1124\/jpet.105.085951","article-title":"Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity","volume":"314","author":"Truong","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.brainres.2007.09.028","article-title":"Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels","volume":"1185","author":"Vergo","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jneumeth.2006.01.002","article-title":"Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry","volume":"155","author":"Volz","year":"2006","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib51","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/syn.20321","article-title":"Kinetic analysis of age-dependent changes in vesicular monoamine transporter-2 function","volume":"60","author":"Volz","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib52","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/jpet.107.126888","article-title":"Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles","volume":"323","author":"Volz","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib53","doi-asserted-by":"crossref","unstructured":"Volz, T.J., Farnsworth, S.J., Rowley, S.D., Hanson, G.R., Fleckenstein, A.E., in press. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. J. Pharmacol. Exp. Ther. (in press).","DOI":"10.1124\/jpet.108.139386"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-8993(80)91265-2","article-title":"Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine","volume":"181","author":"Wagner","year":"1980","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0006-8993(83)90602-9","article-title":"Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes","volume":"270","author":"Wagner","year":"1983","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib56","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nm0696-699","article-title":"Striatal dopamine nerve terminal markers in human, chronic methamphetamine users","volume":"2","author":"Wilson","year":"1996","journal-title":"Nat. Med"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib57","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/WNL.47.3.718","article-title":"Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease","volume":"47","author":"Wilson","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2008.07.002_bib58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-3565(24)37769-9","article-title":"The effects of methamphetamine on the production of free radicals and oxidative stress","volume":"287","author":"Yamamoto","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib59","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0006-8993(97)00771-3","article-title":"Methylphenidate and brain dopamine neurotoxicity","volume":"767","author":"Yuan","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0041-008X(89)90309-8","article-title":"Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine","volume":"100","author":"Zaczek","year":"1989","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.07.002_bib61","doi-asserted-by":"crossref","first-page":"E682","DOI":"10.1208\/aapsj080478","article-title":"Vesicular monoamine transporter 2: role as a novel target for drug development","volume":"8","author":"Zheng","year":"2006","journal-title":"AAPS J."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390808002736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390808002736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T19:25:14Z","timestamp":1738265114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390808002736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":62,"alternative-id":["S0028390808002736"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2008.07.002","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}